Nanobiotix
Nasdaq NBTX · Paris, France
Works in Dermatology · ENT · GI & liver · Oncology · Renal & urogenital · Respiratory · Women's health
Nanobiotix is a clinical trial sponsor based in Paris, France, listed as Nasdaq NBTX. It has 1 active clinical trial with 145 planned participants, across 7 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq NBTX
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Nanobiotix
Nanobiotix is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 145 planned participants, in Dermatology, ENT, GI & liver, Oncology and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
Nanobiotix is based in Paris, France and is listed as Nasdaq NBTX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Nanobiotix; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-10-24.
Approve Suite is not affiliated with Nanobiotix.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.